Patents by Inventor Young Hyo Yu

Young Hyo Yu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6491904
    Abstract: The present invention relates to a topical composition containing human epidermal growth factor (hEGF) and polyoxyethylene-polyoxypropylene copolymer having a viscosity of 4-10 cps at 37° C, 60 rpm as the base for topical formulation to improve the wound healing ability of hEGF.
    Type: Grant
    Filed: September 6, 2000
    Date of Patent: December 10, 2002
    Assignee: Daewoong Pharmaceutical Co., Ltd.
    Inventors: Seung Yeob Lee, Jin Seok Kang, Jeom Soon Shim, Seung Wook Lim, Seung Hee Han, Byoung Kwang Lee, Young Hyo Yu, Jong Keun Chung
  • Publication number: 20020045218
    Abstract: The present invention relates to a recombinant expression vector containing a fusion gene which is prepared by ligating adhesion gene of H. pylori and A2 and B subunit genes of Vibrio cholerae toxin, and a process for preparing a chimeric protein employing a recombinant microorganism transformed with the said expression vector. The recombinant DNA which is designed for convenient expression and gene manipulation, may express a chimeric protein having excellent immunogenicity to H. pylori, which is stable in stomach, and penetrate mucous membrane of stomach easily, finally to stimulate production of sIgA. Accordingly, the chimeric protein expressed from the recombinant DNA may be used as an active ingredient of the diagnostic kit for H. pylori infection and preventive or therapeutic vaccine for H. pylori-associated diseases, and may be used in the production of anti-H. pylori antibody.
    Type: Application
    Filed: January 11, 2001
    Publication date: April 18, 2002
    Applicant: BIOPHARM INC.
    Inventors: Byung-O Kim, Byoung-Kwang Lee, Suk-Won Yoon, Seung-Kook Park, Young-Hyo Yu
  • Publication number: 20010019834
    Abstract: The present invention relates to chimeric proteins consisting of antigenic proteins of Helicobacter pylori and A2 and B subunits of Vibrio cholerae toxin, more specifically, to recombinant DNAs coding for antigenic proteins Helicobacter pylori and A2 and B subunits of Vibrio cholerae toxin, recombinant expression vectors containing the genes, a process for preparing the chimeric proteins employing the recombinant microorganisms transformed with the said expression vectors, and preventive and therapeutic vaccines comprising the chimeric proteins for Helicobacter pylori-associated diseases. The recombinant DNAs which are designed for convenient expression and gene manipulation, can express chimeric proteins having excellent immunogenicity to H. pylori, which are stable in stomach, and penetrate mucous membrane of intestines easily, finally to stimulate production of sIgA. Accordingly, the chimeric proteins expressed from the recombinant DNAs may be used as an active ingredient of the diagnostic kit for H.
    Type: Application
    Filed: September 27, 1999
    Publication date: September 6, 2001
    Inventors: BYUNG-O KIM, SUNG-SEUP SHIN, YOUNG-HYO YU, MYUNG-HWAN PARK, DEOK-JOON CHOI, HYUNG-JIN JUNG
  • Patent number: 5652120
    Abstract: The present invention relates to a novel gene coding human epidermal growth factor("hEGF") and a process for preparing the same employing a recombinant expression vector therefor. The hEGF gene of the invention is designed to contain codons ubiquitous in E. coli and the following restriction sites: HpaI at the 5' terminal, PstI at the 3' terminal and Bpu1102I, NsiI, MluI, Eco47III and AflII at a regular manner within its internal sequence. The present invention also provides a process for preparing hEGF by employing a expression vector pTE105 for hEGF, which contains expression cassette comprising Omp A leader sequence, translation termination sequence and transcription termination sequence and hEGF gene; and, replication origin of pUC19, tetracycline-resistant marker and a par site for stabilization in E. coli. The hEGF is produced massively in E. coli transformed with the pTE105(KCCM 10027).
    Type: Grant
    Filed: December 23, 1994
    Date of Patent: July 29, 1997
    Assignee: Daewoong Pharmaceutical Co., Ltd.
    Inventors: Seung Kook Park, Kang Moon Lee, Kyoo Seung Nho, Yeo Wook Koh, Chang Hyuk Kwon, Ju Young Chung, Young Su Jee, Young Hyo Yu